Predictors of severe immune-related adverse events during first-line immune checkpoint inhibitor therapy for advanced non-small cell lung cancer
Olajumoke A. Olateju(University of Houston), J. Douglas Thornton(University of Houston), Chan Shen(Pennsylvania State University), Meghana V. Trivedi(University of Houston), Ekere James Essien(University of Houston), Meera Patel(Baylor College of Medicine), Tyler J. Varisco(University of Houston), Rajender R. Aparasu(University of Houston)
Cited by 0
Related Papers
Metastasis Dormancy in Estrogen Receptor–Positive Breast Cancer
|Clinical Cancer Research|2013|273
Perspective on Circulating Tumor Cell Clusters: Why It Takes a Village to Metastasize
|Cancer Research|2018|221
Bidirectional Crosstalk between the Estrogen Receptor and Human Epidermal Growth Factor Receptor 2 Signaling Pathways in Breast Cancer: Molecular Basis and Clinical Implications
|Breast Care|2013|200
FOXA1 overexpression mediates endocrine resistance by altering the ER transcriptome and IL-8 expression in ER-positive breast cancer
|Proceedings of the National Academy of Sciences|2016|185
The changing role of ER in endocrine resistance
|The Breast|2015|133